Developments in therapies for AML – chemotherapy, targeted therapy and immunotherapy
Hagop M. Kantarjian
Preliminary results of the AIM trial of ibrutinib and venetoclax in mantle cell lymphoma
Phase II trial of venetoclax monotherapy for relapsed/refractory CLL with 17p deletion
John Gribben et al.
Overview of Bruton’s tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia
Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphoma
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al.